Dyakov I.N.

PHARMACOECONOMIC EVALUATION OF FIRST-LINE COMBINATION THERAPY WITH IMMUNOTHERAPY DRUGS AND PLATINUM-CONTAINING CHEMOTHERAPY IN ADULT PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Article

Зырянов С.К., Дьяков И.Н.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 17. 2024. P.. 22-29

COST-EFFECTIVENESS ANALYSIS OF ACALABRUTINIB IN TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FORM OF MANTLE CELL LYMPHOMA WHO PREVIOUSLY RECEIVED AT LEAST ONE LINE OF THERAPY

Article

Зырянов С.К., Дьяков И.Н.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 17. 2024. P.. 129-136

ECONOMIC EFFECTIVENESS OF FIXED-DOSE COMBINATION OF ALOGLIPTIN AND PIOGLITAZONE IN DIABETES MELLITUS TREATMENT

Article

Zyryanov S.К., Dyakov I.N.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 17. 2024. P.. 442-452

ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ ПРЕПАРАТОВ УПАДАЦИТИНИБА, БАРИЦИТИНИБА И ДУПИЛУМАБА ДЛЯ СИСТЕМНОЙ ТЕРАПИИ ПАЦИЕНТОВ С АТОПИЧЕСКИМ ДЕРМАТИТОМ СРЕДНЕТЯЖЁЛОГО И ТЯЖЁЛОГО ТЕЧЕНИЯ

Article

Зырянов С.К., Дьяков И.Н., Ильина Н.И.

Качественная клиническая практика. 2023. P.. 70-84

UPDATED PHARMACOECONOMIC ANALYSIS OF ATESOLIZUMAB EFFICIENCY COMPARED WITH OTHER PD-1 INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY

Article

Зырянов С.К., Дьяков И.Н.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 16. 2023. P.. 422-430

PHARMACOECONOMIC ANALYSIS OF THE USE OF A FIXED COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL AS MAINTENANCE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE RUSSIAN FEDERATION

Article

Зырянов С.К., Дьяков И.Н.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 15. 2022. P.. 188-198

PHARMACOECONOMICS ANALYSIS OF USING A FIXED COMBINATION OF BUDESONIDE/FORMOTEROL IN PATIENTS WITH ASTHMA IN THE HEALTH CARE SYSTEM OF THE RUSSIAN FEDERATION

Article

Зырянов С.К., Дьяков И.Н., Айсанов З.Р.

Terapevticheskii Arkhiv. Vol. 94. 2022. P.. 850-858

ФАРМАКОЭКОНОМИЧЕСКОЕ СРАВНЕНИЕ АНАЛОГОВ ИНСУЛИНА ВТОРОГО ПОКОЛЕНИЯ И ПРЕПАРАТОВ НА ИХ ОСНОВЕ

Article

Дьяков И.Н., Зырянов С.К.

Качественная клиническая практика. 2021. P.. 4-15

ФАРМАКОЭКОНОМИЧЕСКИЕ ХАРАКТЕРИСТИКИ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА-1 И ПРЕПАРАТОВ НА ИХ ОСНОВЕ

Article

Дьяков И.Н., Зырянов С.К.

Качественная клиническая практика. 2021. P.. 4-15

PHARMACOECONOMIC ASPECTS OF ORAL VINORELBINE APPLICATION: A BUDGET IMPACT ANALYSIS CONSIDERING THE NEW REGISTERED PRICE

Article

Иванов Д.А., Дьяков И.Н., Зырянов С.К.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 14. 2021. P.. 103-114

PHARMACOECONOMIC ANALYSIS OF TALIGLUCERASE ALFA USED IN THE RUSSIAN FEDERATION FOR GAUCHER’S DISEASE

Article

Дьяков И.Н., Зырянов С.К.

Medical Technologies. Assessment and Choice. 2021. P.. 54-62

ЭКОНОМИЧЕСКАЯ СТОРОНА ИНТЕНСИФИКАЦИИ ПЕРОРАЛЬНОЙ САХАРОСНИЖАЮЩЕЙ ТЕРАПИИ АГОНИСТАМИ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА-1

Article

Зырянов С.К., Дьяков И.Н.

Качественная клиническая практика. 2021. P.. 4-15

FN3 PROTEIN FRAGMENT CONTAINING TWO TYPE III FIBRONECTIN DOMAINS FROM B. LONGUM GT15 BINDS TO HUMAN TUMOR NECROSIS FACTOR ALPHA IN VITRO

Article

Dyakov I.N., Mavletova D.A., Chernyshova I.N., Snegireva N.A., Gavrilova M.V., Bushkova K.K., Dyachkova M.S., Alekseeva M.G., Danilenko V.N.

Anaerobe. Vol. 65. 2020.

THE PHARMACOECONOMIC EFFICACY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA

Article

Зырянов С.К., Дьяков И.Н., Жуперин А.А., Егорова Д.А., Мосолова Е.С.

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. Vol. 120. 2020. P.. 82-91

COST ANALYSIS OF DUAL ANTIPLATELET THERAPY WITH PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION

Article

Дьяков И.Н., Ушкалова Е.А.

Российский кардиологический журнал. Vol. 25. 2020. P.. 96-106

PHARMACOECONOMIC FEASIBILITY OF USING THE DRUG UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE HEALTHCARE SYSTEM OF THE RUSSIAN FEDERATION

Article

Лила А.М., Зырянов С.К., Дьяков И.Н.

Качественная клиническая практика. 2020. P.. 40-51

PHARMACOECONOMIC COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN DIABETES MELLITUS TYPE 2

Article

Дьяков И.Н., Зырянов С.К.

Качественная клиническая практика. 2020. P.. 4-14

PHARMACOECONOMIC EFFICACY OF ATESOLIZUMAB COMPARED WITH OTHER PD-1 INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY

Article

Zyryanov S.K., Diyakov I.N.

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Vol. 13. 2020. P.. 5-12

ФАРМАКОЭКОНОМИЧЕСКАЯ ОЦЕНКА ПРИМЕНЕНИЯ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ЦЕФТАЗИДИМ + [АВИБАКТАМ] ПРИ ЛЕЧЕНИИ НОЗОКОМИАЛЬНЫХ ПНЕВМОНИЙ, ВЫЗВАННЫХ КАРБАПЕНЕМОРЕЗИСТЕНТНЫМИ ЭНТЕРОБАКТЕРИЯМИ И ОСЛОЖНЕННЫХ БАКТЕРИЕМИЕЙ

Article

Зырянов С.К., Дьяков И.Н.

Medical Technologies. Assessment and Choice. 2020. P.. 50-58

ФАРМАКОЭКОНОМИЧЕСКОЕ СРАВНЕНИЕ ФИКСИРОВАННОЙ КОМБИНАЦИИ ИНСУЛИНА ГЛАРГИН И ЛИКСИСЕНАТИДА С "СЕМЕЙСТВОМ" ИНСУЛИНА ДЕГЛУДЕК ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА

Article

Дьяков И.Н., Зырянов С.К.

Качественная клиническая практика. 2020. P.. 4-14

CLINICAL AND ECONOMIC EFFICIENCY OF TREATMENT WITH CARIPRAZINE IN SCHIZOPHRENIA

Article

Dyakov I.N., Zyryanov S.K.

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. Vol. 119. 2019. P.. 66-77

ЭКОНОМИЧЕСКАЯ ЦЕЛЕСООБРАЗНОСТЬ ПРИМЕНЕНИЯ ИММУНОБИОЛОГИЧЕСКОГО ПРЕПАРАТА ОМАЛИЗУМАБ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ БРОНХИАЛЬНОЙ АСТМОЙ В УСЛОВИЯХ ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ

Article

Зырянов С.К., Белевский А.С., Дьяков И.Н.

Астма и аллергия. 2019. P.. 28-37

ECONOMIC PERSPECTIVES FOR EFFECTIVE CONTROL OF DIABETES MELLITUS TYPE 2 WITH FIXED COMBINATION OF BASAL INSULIN ANALOG AND GLP-1 AGONIST

Article

Zyryanov S.K., Dyakov I.N.

Качественная клиническая практика. 2019. P.. 4-14

PHARMACOECONOMIC EVALUATION OF CEFTOLOSAN + TASOBACTAM IN THE TREATMENT OF COMPLICATED NOSOCOMIAL INTRA-ABDOMINAL INFECTIONS

Article

Zyryanov S.K., Dyakov I.N., Khachatryan N.N.

Качественная клиническая практика. 2019. P.. 55-69

CLINICAL AND ECONOMIC ANALYSIS OF THE AXITINIB AS A SECOND-LINE TARGET THERAPY FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Article

Zyrianov S.K., Diakov I.N.

Medical Technologies. Assessment and Choice. Vol. 36. 2019. P.. 59-68

Records list

PHARMACOECONOMIC EVALUATION OF FIRST-LINE COMBINATION THERAPY WITH IMMUNOTHERAPY DRUGS AND PLATINUM-CONTAINING CHEMOTHERAPY IN ADULT PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

COST-EFFECTIVENESS ANALYSIS OF ACALABRUTINIB IN TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FORM OF MANTLE CELL LYMPHOMA WHO PREVIOUSLY RECEIVED AT LEAST ONE LINE OF THERAPY

ECONOMIC EFFECTIVENESS OF FIXED-DOSE COMBINATION OF ALOGLIPTIN AND PIOGLITAZONE IN DIABETES MELLITUS TREATMENT

UPDATED PHARMACOECONOMIC ANALYSIS OF ATESOLIZUMAB EFFICIENCY COMPARED WITH OTHER PD-1 INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY

PHARMACOECONOMIC ANALYSIS OF THE USE OF A FIXED COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL AS MAINTENANCE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE RUSSIAN FEDERATION

PHARMACOECONOMICS ANALYSIS OF USING A FIXED COMBINATION OF BUDESONIDE/FORMOTEROL IN PATIENTS WITH ASTHMA IN THE HEALTH CARE SYSTEM OF THE RUSSIAN FEDERATION

ФАРМАКОЭКОНОМИЧЕСКОЕ СРАВНЕНИЕ АНАЛОГОВ ИНСУЛИНА ВТОРОГО ПОКОЛЕНИЯ И ПРЕПАРАТОВ НА ИХ ОСНОВЕ

ФАРМАКОЭКОНОМИЧЕСКИЕ ХАРАКТЕРИСТИКИ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА-1 И ПРЕПАРАТОВ НА ИХ ОСНОВЕ

PHARMACOECONOMIC ASPECTS OF ORAL VINORELBINE APPLICATION: A BUDGET IMPACT ANALYSIS CONSIDERING THE NEW REGISTERED PRICE

PHARMACOECONOMIC ANALYSIS OF TALIGLUCERASE ALFA USED IN THE RUSSIAN FEDERATION FOR GAUCHER’S DISEASE

ЭКОНОМИЧЕСКАЯ СТОРОНА ИНТЕНСИФИКАЦИИ ПЕРОРАЛЬНОЙ САХАРОСНИЖАЮЩЕЙ ТЕРАПИИ АГОНИСТАМИ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА-1

FN3 PROTEIN FRAGMENT CONTAINING TWO TYPE III FIBRONECTIN DOMAINS FROM B. LONGUM GT15 BINDS TO HUMAN TUMOR NECROSIS FACTOR ALPHA IN VITRO

THE PHARMACOECONOMIC EFFICACY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA

COST ANALYSIS OF DUAL ANTIPLATELET THERAPY WITH PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION

PHARMACOECONOMIC FEASIBILITY OF USING THE DRUG UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE HEALTHCARE SYSTEM OF THE RUSSIAN FEDERATION

PHARMACOECONOMIC COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN DIABETES MELLITUS TYPE 2

PHARMACOECONOMIC EFFICACY OF ATESOLIZUMAB COMPARED WITH OTHER PD-1 INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY

ФАРМАКОЭКОНОМИЧЕСКОЕ СРАВНЕНИЕ ФИКСИРОВАННОЙ КОМБИНАЦИИ ИНСУЛИНА ГЛАРГИН И ЛИКСИСЕНАТИДА С "СЕМЕЙСТВОМ" ИНСУЛИНА ДЕГЛУДЕК ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА

CLINICAL AND ECONOMIC EFFICIENCY OF TREATMENT WITH CARIPRAZINE IN SCHIZOPHRENIA

ECONOMIC PERSPECTIVES FOR EFFECTIVE CONTROL OF DIABETES MELLITUS TYPE 2 WITH FIXED COMBINATION OF BASAL INSULIN ANALOG AND GLP-1 AGONIST

PHARMACOECONOMIC EVALUATION OF CEFTOLOSAN + TASOBACTAM IN THE TREATMENT OF COMPLICATED NOSOCOMIAL INTRA-ABDOMINAL INFECTIONS

CLINICAL AND ECONOMIC ANALYSIS OF THE AXITINIB AS A SECOND-LINE TARGET THERAPY FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Other authors

Rodionova Irina

Mischenko A.V.